Diagnosis and Management of Metastatic CRC: State-of-the-Art Oncology Nursing Practice

Last Modified: July 25, 2014

Share article


Co-Provided by:

AACME xme

Support for this activity has been made possible through an educational grant from Bayer HealthCare Pharmaceuticals.

Release date: July 24, 2014
Expiration date: July 24, 2015
Estimated time to complete: 1.25 hours
Activity URL:  www.oncolink.org/resources/article.cfm?aid=7068&id=7068&c=412
Post-Test: http://www.academycme.org/actID=13XM11W

Target Audience

This activity has been designed to meet the educational needs of oncology nurses and nurse practitioners involved in the care of patients with metastatic colorectal cancer (mCRC).

Activity Description

More than 140,000 adults in the US will be diagnosed with CRC this year. At the time of diagnosis, a quarter of these patients will have metastases, and 50% to 60% of the remainder will develop metastasis during the course of treatment.

A number of drugs have demonstrated activity in mCRC. However, adherence to guideline-recommended treatment for mCRC is suboptimal, and many patients receive treatment outside of evidence-based, best-practice standards. Because adherence to guidelines has been found to improve outcomes in mCRC, it is imperative that all healthcare professionals improve their ability to adhere to evidence-based practices for the management of this condition.

Oncology nursing professionals play a critical role in the management of cancers, including mCRC. Given the major role of oncology nurses and nurse practitioners as well as the challenges they face while involved in CRC management, it is critical that these individuals are knowledgeable and competent in all aspects of therapy and management. This will allow them to improve their abilities and role within the healthcare team managing these patients.

Activity Faculty

Carolyn Grande, CRNP, AOCNP
Nurse Practitioner, Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Learning Objectives

Upon completion of this educational activity, learners should be better able to:

  • Distinguish guideline-recommended treatment options for mCRC and the evidence that supports each therapy
  • Summarize recent changes to current mCRC guidelines, including the addition of new therapeutic options and opportunities for more targeted therapy in select patient populations
  • Recognize toxicities associated with chemotherapy and targeted therapies for treatment of mCRC and develop individual plans to manage these complications
  • Identify and distinguish resources and guidelines designed to manage treatment-related toxicities in mCRC therapy

Accreditation and Credit Designation

Nursing Professionals

American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

American Academy of CME, Inc. designates this educational activity for 1.25 contact hours (including 1.25 pharmacotherapeutic contact hours).

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosures are as follows:

Activity Faculty

Carolyn Grande, CRNP, AOCNP, has received grant/research support as a sub-investigator from Bayer HealthCare Pharmaceuticals, Exelixis, Novartis Pharmaceuticals, Roche Pharmaceuticals, and Eisai Pharmaceuticals.

Planners/Reviewers

Angela Laffan, RN, ANP, AOCN, Nurse Practitioner, GI Oncology, Stanford Hospital. Ms. Laffan is a shareholder in Exact Sciences.

Linda Mai Penwarden, RN, MN, AOCN, Oncology Clinical Nurse Specialist, St. Luke's Mountain States Tumor Institute. Ms. Penwarden is on the advisory board for Amgen Oncology; an employee of St. Luke's Mountain States Tumor Institute; the promotional speaker's bureau for Eisai Pharmaceuticals; and has a contract with the American Society of Clinical Oncology for their Quality Oncology Practice Initiative Certification Program.

Emily Petito, MSN, CRNP, Nurse Practitioner, Division of Medical Oncology, Johns Hopkins University. Ms. Petito has no relevant financial relationships to disclose.

Fredrica "Ricky" Preston, RNC, NP, AOCN, Nurse Practitioner, Medical Oncology, MGH North Shore Cancer Center. Ms. Preston has no relevant financial relationships to disclose.

Carole Viele, RN, MS, CNS, Associate Clinical Professor, Department of Physiological Nursing University of California, San Francisco. Ms. Viele is on the advisory board for Novartis and the promotional speaker's bureaus for Novartis, Merck, and Celgene.

John JD Juchniewicz, MCIS, CCMEP, Paul J. Miniter, MS, and Natalie Kirkwood, RN, BSN, JD, Lead Nurse Planner; American Academy of CME: No relevant financial relationships with any commercial interests.

Elizabeth Paczolt, MD, Mindy Aratow, Pat McCollum; Excellence in Medical Education: No relevant financial relationships with any commercial interests.

This activity will not review off-label or investigational information.

Disclaimer

The opinions expressed in this educational activity are those of the faculty, and do not represent those of Academy, Excellence in Medical Education, or American Nurses Credentialing Council's Commission on Accreditation. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE credit for your participation, please complete the post assessment (achieving a passing score of 70% or higher) and program evaluation. If asked, the activity ID is 13XM11W. Your certificate can be printed immediately.

Hardware/Software Requirements

Participants will need to have QuickTime, Windows Media Player, or VLC to view the program.

Privacy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm

Contact

For any questions, please contact: CEServices@academycme.org

Proceed to Activity

Copyright © 2014. This CNE-certified activity is held as copyrighted © by American Academy of CME and Excellence in Medical Education. Through this notice, the Academy and Excellence in Medical Education grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).


News
ASCO: Regorafenib Improves Survival in Metastatic CRC

Jan 20, 2012 - For patients with metastatic colorectal cancer that has progressed after standard therapies, treatment with regorafenib significantly improves overall survival and progression-free survival compared with placebo, according to a study presented at the American Society of Clinical Oncology's annual Gastrointestinal Cancers Symposium, held from Jan. 19 to 21 in San Francisco.



OncoLink Treatment Binder

Select the side effects and forms for your patient's treatment binder

Learn More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More